Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +2.07% 12.30p 11.80p 12.30p 12.30p 12.00p 12.05p 439,775 16:22:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -7.0 -4.8 - 17.15

Immupharma Share Discussion Threads

Showing 33776 to 33799 of 33800 messages
Chat Pages: 1352  1351  1350  1349  1348  1347  1346  1345  1344  1343  1342  1341  Older
DateSubjectAuthorDiscuss
07/12/2018
08:24
Another placing before the next results on Q3 on the failed drug. Lemmings and mushrooms only now.
ken chung
07/12/2018
08:10
Go on, tell me which parts constitutes a 'pretty good update'?
nobbygnome
07/12/2018
07:52
Eh no one ever said that ? Your just talking to yourself mate.Fact is there is a lot of uncertainty around the nomad and this should put it to bed. That's all simple as that
kirk 6
07/12/2018
07:47
The early bird catches the worm...... Point out to me which part exactly constitutes a 'pretty good update'? If a company can't sort out a new Nomad, that is a sorry state of affairs ....
nobbygnome
07/12/2018
07:44
Pretty good update and this could well put all the uncertainty to bed:"With active discussions ongoing regarding the appointment of a new NOMAD, we look forward to updating the market and shareholders again in the near future."
kirk 6
07/12/2018
07:43
Yet you have to be the first to comment lol sad
kirk 6
07/12/2018
07:34
Well a completely nothing announcement this morning; no wonder they put it out on a Friday. But never mind, the board will keep on taking their big salaries wasting your shareholder funds whilst doing virtually nothing. You shareholder should be agitating for changes on the board and some real action. It is all so sad....and predictable!
nobbygnome
05/12/2018
12:52
No I don't and I don't want to be a guinea pig.
fuji99
05/12/2018
09:07
"and their stupidity in giving placebo to desperate poor people" Do you actually understand what a placebo is, and why it is used in clinical trials?
stockriser
05/12/2018
08:57
Due to their previous "clarity" in everything and their stupidity in giving placebo to desperate poor people, never believe whatever they say anymore. Expect a fund raising exercise to dilute the share price to reach 1 - 2 p to become insolvent then vanish.
fuji99
03/12/2018
13:52
Classic pile of worthless dog dung heading for 4p. Lemmings and mushrooms only now.
ken chung
03/12/2018
11:19
Talk of fantastic news this week
troajan1
30/11/2018
14:26
Pump over...
michbens
30/11/2018
10:52
Mmmm....gone off the boil, 1030hrs, onwards. f
fillipe
30/11/2018
08:22
It needs positive news for a 'real' rise - at the moment its just pi buys leading to additional AT robot buys and sells leading to robot sells imho
mister md
30/11/2018
07:16
This is due a rise?
amadeus888
30/11/2018
00:54
Is it game is on again?
top tips
29/11/2018
17:21
SK - interesting view thanks; not sure of any of the 3 but share price move interesting.
colsmith
29/11/2018
16:08
I'm liking this
knowing
29/11/2018
16:06
IMM certainly being well taken with very close to the ask of 14p now being regularly paid. Weekend press? f P.S. make that 14.95p showing as the lowest ask....L2. f
fillipe
29/11/2018
13:20
I'll take 1 and 2...so it's probably 3 lol
glennrcharles
29/11/2018
13:18
Lets hope 1 and 2 !!! Bought a modest holding back again after losing over £10k last time after the mixed results.
joeblogg2
29/11/2018
13:14
Well the share price is looking perky. In my view there are three possible reasons: 1. Shareholder anticipation of a Ureka deal. NASH is a hot pharma area at the moment. It was announced yesterday that Genentech bought Jecure Therapeutics. See the very interesting article below about the Pharma race to acquire NASH hTTp://www.pmlive.com/pharma_news/roche_enters_nash_race_with_deal_to_buy_jecure_1266324 "Roche has joined the melee of pharma companies trying to claim a share of the market for non-alcoholic steatohepatitis (NASH) drugs, cutting a deal to acquire US start-up Jecure Therapeutics." "NASH is a hot topic in pharma development at the moment, with a host of companies vying to bring forward new treatments for the disease, which is viewed as an emerging health crisis - and an untapped pharma market." "Some predictions put the market potential at $20bn to $35bn a year." Now we know from the Interims that: "Ureka, ImmuPharma's wholly owned subsidiary, based in Bordeaux, which is carrying out research into treatments for Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) has recently demonstrated success in recognised preclinical studies. Following an extensive review by ImmuPharma's Board of directors, it has been decided that Ureka, whilst having exciting and innovative technologies, is not part of the ongoing strategy of ImmuPharma, which is now fully focused on utilising its resources to develop late stage assets. As such, ImmuPharma, with its advisors, will now commence a process of considering all opportunities to divest Ureka. The intention is to allow ImmuPharma to divest Ureka, whilst still retaining an interest in any future commercial success." 2) Shareholder anticipation of more Lupuzor news. YoungHarry has stated "Mid November / early December, full analyses of PIII trial" and "The company will receive the full data from the PIII trial by the of end July / mid August, analysis will take a further two months and answers to key research issues will take a further two months after that. The key research findings will be published in peer reviewed journals." 3) Misplaced shareholder anticipation Take your pick.
sicilian_kan
29/11/2018
12:50
No doubt it's another pump and dump..Just look at Twitter. Same old characters are back in after it dropped to 10p.Suddently the rumours reappear after a 5 day period of silence
michbens
Chat Pages: 1352  1351  1350  1349  1348  1347  1346  1345  1344  1343  1342  1341  Older
Your Recent History
LSE
IMM
Immupharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181215 21:47:19